News
-

The 2005 Oxytocin Trust Study: What It Found and Missed
One 2005 lab game in 194 male students launched the 'trust hormone' slogan. Two decades of larger follow-up trials tell a much narrower story.
-

Ozempic Before Colonoscopy: Do You Need to Stop?
Taking Ozempic before a colonoscopy does not mean an automatic pause for every patient. Your prescriber and endoscopy team weigh stomach emptying, bowel prep quality, and your symptoms to set your plan.
-

10 Questions to Ask Before Semax or Selank
Semax and Selank are not FDA-approved, and neither peptide has a U.S. prescribing label. A medical review relies on small human studies, foreign product sheets, and your health history.
-

Rudman Growth Hormone Study: What the 1990 Trial Showed
A six-month trial of 21 older men changed how people talk about human growth hormone and aging. Its actual measurements were much narrower than the anti-aging claims built on top of it.
-

Waist to Height Ratio: What Your Numbers Mean
Dividing your waist size by your height gives a quick picture of abdominal fat that BMI alone can miss. Here is how clinical guidelines read the numbers and what major medication trials actually measured.
-

MOTS-c and Metformin: Can You Take Them Together?
No published human trial administering MOTS-c with metformin was identified in PubMed and ClinicalTrials.gov searches on October 17, 2026. Combined safety and clinical effects remain unknown, though AMPK research, a human biomarker study, and metformin's label offer context.
-

Wegovy Pill Prescribing Information: What It Says
Novo Nordisk's June 2026 package insert combines the weekly Wegovy shot and the daily Wegovy tablet into one document. Here is what the tablet sections say about uses, morning dosing rules, side effects, and safety warnings.
-

Who Discovered DSIP? The 1977 Basel Sleep Study
Swiss researchers Guido A. Schoenenberger and Marcel Monnier characterized DSIP in Basel in 1977 after testing rabbit blood for a sleep factor. A 2006 review left its natural origin unresolved, and a 2011 precursor proposal did not settle it.
-

KLOW vs BPC-157: Four-Peptide Blend or One Alone?
KLOW combines BPC-157 with three other peptides in one blend, while BPC-157 alone gives you a single active ingredient. PubMed and ClinicalTrials.gov searches on October 17, 2026 identified no human or animal study comparing the four-peptide blend with BPC-157 alone.
-

The Ozempic Gastroparesis Study: What JAMA Found
The 2023 JAMA paper behind 'stomach paralysis' headlines was an insurance-claims letter, not a clinical trial. Here is what its numbers actually showed — and what later studies found.
-

Do Peptides Cause Cancer? What Human Studies Show
Human studies haven't established that BPC-157, TB-500 or growth-hormone peptides cause cancer. Long-term risk remains open and differs by compound.
-

GHK-Cu vs Retinol: Which Has Better Evidence?
Retinoids have stronger human evidence for wrinkles. Copper-peptide studies are smaller, and skin irritation and delivery route change the comparison.
-

Semax Dosage: What Russian Labels and Studies Say
Russian labels and small studies report very different Semax amounts. A prescriber sets any actual dose, timing, and follow-up.
-

Thanksgiving on Tirzepatide: Dinner and Doses
Holiday dinner can feel different on tirzepatide. The label facts explain fullness, stomach symptoms, dose timing and medicine storage around guests.
-

Wolverine Peptide Side Effects: What Is Known?
Wolverine's human safety profile is still uncertain. Reported reactions, animal findings, and preparation risks help explain what needs a clinician's attention.
-

FibroScan Results Explained: Fat and Scarring
CAP estimates liver fat; stiffness helps assess scarring. Here’s how FibroScan, FIB-4, MRI and biopsy numbers fit together, with examples from trials.
-

10 Questions to Ask Before GHK-Cu
Ten questions cover the evidence, copper exposure, medical history and follow-up that a GHK-Cu visit needs to address.
-

SURMOUNT-MAINTAIN Results: What 5 mg Kept Off
Reducing tirzepatide to 5 mg preserved more weight loss than stopping in this trial. Keeping the higher dose preserved more, and the lower-dose group still regained some weight.
-

Foundayo Prescribing Information, Explained
Foundayo’s label describes a daily weight-management pill, gradual dose increases and specific interaction checks. Here’s what each key section means.
-

GLP-1 After Bariatric Surgery: A Provider’s Review
Weight regain can lead to another treatment discussion. Surgery type, reflux, nutrition, and blood-sugar history shape whether a GLP-1 fits.
Page 4 of 27 · 528 articles